Fast Track Designation from the US FDA for IBI363 in Squamous NSCLC
Dr. Hui Zhou, Senior Vice President of Innovent, stated, “We are pleased that IBI363 has been granted Fast Track Designation by the FDA for sqNSCLC, following its previous designation for melanoma. Earlier, we reported that in an expanded cohort of sqNSCLC patients, IBI363 showed a trend toward improved ORR and DCR at higher doses, along with a manageable safety profile. The latest PFS data from the 3 mg/kg dose group after longer follow-up further strengthens our confidence in IBI363’s potential as an immunotherapy offering long-term benefits to patients. We will present the relevant data at upcoming academic conferences this year. More encouragingly, IBI363 has demonstrated potent anti-tumor activity regardless of PD-L1 expression levels. This suggests that IBI363 may not only advance treatment for immunotherapy-resistant populations but also for cold tumors with low or no PD-L1 expression. In addition to lung cancer, we have observed encouraging efficacy signals in cold tumors, including colorectal cancer and mucosal melanoma, with melanoma already advancing to pivotal clinical stages. Moving forward, we will continue to explore IBI363 in early-line treatment and in combination therapies.”
Share:
More News
“Today’s milestone brings us one step closer to providing an effective dual immunotherapy treatment option to adult and pediatric patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer,” said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. “We look forward to potentially bringing
“The FDA’s clearance, signaling the initiation of our Phase I study for LTZ-301, represents a significant milestone for the company,” said Robert Li, Ph.D., Founder and CEO of LTZ. “We look forward to advancing our lead asset into the clinic to evaluate our myeloid engager approach and its potential as
“Eikon has made remarkable progress in advancing a pivotal-stage clinical pipeline and early-stage development program powered by our single-molecule tracking technology and the deep expertise of our multidisciplinary team. With clinical studies now operating in 28 countries, across 5 continents, we are accelerating the development of much-needed therapies while continuing
AIM CEO Thomas K. Equels stated: “Unlike with many pancreatic cancer studies where accrual can be a major obstacle, we expect to continue to enroll subjects in Phase 2 of DURIPANC at a steady pace.”
